Dr. Bankier recently worked together with Olympus on a white paper, "Performance and Benefit of SeleCT Enhanced by Deep Learning-based Artificial Intelligence," evaluating a deep learning-based version of the SeleCT QCT analysis software, finding that the "[deep learning version of] SeleCT provides a robust and consistent assessment…characterized by excellent overall agreement with results from the predicate software (93% to 96%) and very high to excellent sensitivity (89% or 97%) and specificity (87% to 97%)." Use of deep learning is based on the idea that sophisticated computer algorithms can improve in effectiveness over time by using supervised data input from historical cases. Customers interested in the white paper should request it from their Olympus representative.
"We are pleased to work with Olympus, a company with breakthrough medical technology for addressing severe emphysema using minimally invasive techniques," said Dave Hannes, CEO, Imbio. "Providing our device and pharma partners with companion imaging solutions that add value and help deliver better patient care is a key part of Imbio's mission. We are proud that accurate patient selection will mean improved patient experience for thousands of COPD sufferers."
Ad Statistics
Times Displayed: 2147
Times Visited: 10 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
During a bronchoscopic lung volume reduction (BLVR) procedure, the Spiration Valve System, a one-way endobronchial valve, is placed into selected airways of emphysematous lungs, redirecting air away from diseased parts of the lung to healthier parts. This treatment has been shown to allow patients with severe emphysema to breathe more easily and experience improvement in their quality of life.ii
Emphysema is a progressive disease that has affected 3.4 million people in the U.S., according to the Centers for Disease Control and Prevention.iii The disease causes a loss of elasticity in lung tissue and enlargement of the alveoli. As a result, emphysematous lobes become hyperinflated, causing shortness of breath. The results of the randomized trials of valve therapy have led to the inclusion of BLVR therapy as an important component of the clinical therapy recommendationsiv,v for the underserved patient population with severe emphysema.
For information about Olympus Spiration Valve System endobronchial valves, visit these dedicated websites:
For doctors: https://svs.olympusamerica.com/prescriptive-information
Or for patients and their families: https://svs.olympusamerica.com/patients-and-family.
